Gout medication tested for type 1 diabetes
US researchers are recruiting 500 patients with type 1 diabetes to test if the gout medication allopurinol delays the onset of kidney disease.
If the 42-month study succeeds, the decades-old medication could be to diabetic kidney disease what baby aspirin is to heart attacks, says endocrinologist Dr Luiza Caramori.
The drug could delay the need for dialysis and kidney transplants by eight to 10 years, she says.
While the University of Minnesota study is limited to subjects with type 1 diabetes, Dr Caramori says positive findings are likely also to benefit